Alnylam Pharmaceuticals Stock Performance
| ALNY Stock | USD 143.31 0.40 0.28% |
The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Alnylam Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Alnylam Pharmaceuticals is expected to be smaller as well. Alnylam Pharmaceuticals has an expected return of -0.35%. Please make sure to confirm Alnylam Pharmaceuticals standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Alnylam Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.28) | Five Day Return (0.97) | Year To Date Return (26.48) | Ten Year Return 193.25 | All Time Return 2.3 K |
1 | Disposition of 878 shares by Franchini Indrani Lall of Alnylam Pharmaceuticals subject to Rule 16b-3 | 02/27/2024 |
2 | Samenvatting Alnylam rapporteert positieve KARDIA-2 topline onderzoeksresultaten die een klinisch belangrijke vermindering van de bloeddruk aantonen wanneer zil... | 03/05/2024 |
3 | Alnylam Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi Korsinsky for Details- ALNY | 03/22/2024 |
4 | Why Alnylam Pharmaceuticals Stock Might be a Great Pick | 04/08/2024 |
5 | Alnylam Pharmaceuticals, Inc. Investigation Ongoing Contact Levi Korsinsky About Potential Securities Fraud Allegations - ALNY | 04/09/2024 |
6 | ALNY STOCK ALERT Levi Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation | 04/10/2024 |
7 | Healing Realty Trust Appoints Three Advisory Board Members Across Strategic Sectors | 04/16/2024 |
8 | ALNY ALERT Levi Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc. | 04/18/2024 |
9 | Ad hoc announcement pursuant to Art. 53 LR Roche sales increase by 2 percent in first quarter with both divisions growing in high single digit ex COVID-19 | 04/24/2024 |
10 | Ocugen to Report Q1 Earnings Whats in the Cards | 04/26/2024 |
| Begin Period Cash Flow | 866.4 M |
Alnylam |
Alnylam Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 18,096 in Alnylam Pharmaceuticals on January 28, 2024 and sell it today you would lose (3,765) from holding Alnylam Pharmaceuticals or give up 20.81% of portfolio value over 90 days. Alnylam Pharmaceuticals is currently does not generate positive expected returns and assumes 2.1109% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Alnylam, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alnylam Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alnylam Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alnylam Pharmaceuticals, and traders can use it to determine the average amount a Alnylam Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1644
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALNY |
Estimated Market Risk
| 2.11 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alnylam Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alnylam Pharmaceuticals by adding Alnylam Pharmaceuticals to a well-diversified portfolio.
Alnylam Pharmaceuticals Fundamentals Growth
Alnylam Stock prices reflect investors' perceptions of the future prospects and financial health of Alnylam Pharmaceuticals, and Alnylam Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alnylam Stock performance.
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0478 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 18.35 B | ||||
| Shares Outstanding | 126.45 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 142.92 X | ||||
| Price To Sales | 10.27 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (228.12 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | (1.75) X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Earnings Per Share | (3.52) X | ||||
| Market Capitalization | 18.18 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
About Alnylam Pharmaceuticals Performance
To evaluate Alnylam Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Alnylam Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Alnylam Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Alnylam Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Alnylam's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 104.82 | 99.58 | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.1) | (0.10) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | 2.00 | 2.10 |
Things to note about Alnylam Pharmaceuticals performance evaluation
Checking the ongoing alerts about Alnylam Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alnylam Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alnylam Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 1.83 B. Net Loss for the year was (440.24 M) with profit before overhead, payroll, taxes, and interest of 868.6 M. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Ocugen to Report Q1 Earnings Whats in the Cards |
- Analyzing Alnylam Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alnylam Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Alnylam Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alnylam Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alnylam Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alnylam Pharmaceuticals' stock. These opinions can provide insight into Alnylam Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.52) | Revenue Per Share 14.637 | Quarterly Revenue Growth 0.312 | Return On Assets (0.05) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.